Apr 29, 2026 07:00AM
Apr 29, 2026 06:09AM
Apr 29, 2026 03:23AM
Apr 28, 2026 04:00PM
Mar 24, 2026 10:30AM
Mar 2, 2026 07:37AM
Feb 20, 2026 07:01AM AstraZeneca's CALQUENCE plus venetoclax wins FDA approval for CLL treatment
Feb 20, 2026 07:00AM
Feb 13, 2026 01:30PM
Feb 10, 2026 07:05AM
Feb 10, 2026 07:00AM
Feb 10, 2026 04:52AM
Feb 9, 2026 12:00PM
Jan 14, 2026 01:11AM Guggenheim Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)
Jan 5, 2026 04:09AM
Dec 3, 2025 02:59AM
Nov 26, 2025 08:00AM
Nov 10, 2025 04:36AM
Nov 6, 2025 07:00AM
Nov 6, 2025 06:56AM
Nov 6, 2025 05:58AM AstraZeneca (AZN) Tops Q3 EPS by 122c; offers guidance
Nov 6, 2025 12:00AM
Oct 16, 2025 07:13AM
Jul 29, 2025 07:00AM
Jul 29, 2025 05:05AM
Jul 29, 2025 02:05AM
Jun 12, 2025 07:53AM
May 2, 2025 08:30AM Bernstein explains why share price rally in this pharma stock should continue
Apr 29, 2025 03:31AM
Apr 29, 2025 02:00AM
Apr 24, 2025 05:00PM
Apr 22, 2025 06:00AM
Mar 3, 2025 08:00AM
Feb 26, 2025 07:02AM
Feb 14, 2025 04:30AM This pharma stock has rich catalyst path, attractive valuation: BofA
Feb 12, 2025 05:45AM
Feb 10, 2025 10:00AM
Feb 10, 2025 05:32AM
Feb 6, 2025 07:00AM
Feb 6, 2025 05:14AM
Jan 17, 2025 07:00AM
Jan 17, 2025 07:00AM CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
Nov 20, 2024 12:34AM
Nov 18, 2024 06:22AM
Nov 12, 2024 07:09AM
Nov 12, 2024 07:01AM
Nov 12, 2024 07:00AM
Nov 12, 2024 07:00AM
Nov 12, 2024 03:46AM AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments
Jul 25, 2024 08:17AM

1,199,404 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All